GlaxoSmithKline has sold two travel vaccines to a Danish biotechnology company for almost €1 billion (US$1.11 billion) as it refocuses on its most profitable and innovative products, reported The Financial Times.
The UK drugmaker announced the decision to relinquish the brands, acquired from rival Novartis in 2015 as part of an asset swap that secured the Swiss company’s vaccines business, “supports GSK’s strategic intent to increase focus and reinvest in growth assets, innovation and a simplified supply chain in its vaccines business.”
GSK announced in December that it would split into a standalone pharmaceuticals and vaccines business and a separate consumer health joint venture with Pfizer, giving up on its current diversified corporate model.
On Monday, October 21, it announced the divestment of travel vaccines Rabipur, sold as Rabavert in the US, for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic. The Danish company specialises in the research, development, and manufacture of cancer immunotherapies and vaccines for infectious diseases.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Apple Prevails in Dismissal of Crypto-Payment Antitrust Lawsuit
Mar 27, 2024 by
CPI
Amazon Fined in Poland for Misleading Customers
Mar 27, 2024 by
CPI
Credit Card Rewards Under Threat as Visa, Mastercard Settlement Impacts Swipe Fees
Mar 27, 2024 by
CPI
UK Fashion Giants Commit to Honest Environmental Claims
Mar 27, 2024 by
CPI
Former Traders Lose Appeal Against Libor Rigging Conviction
Mar 27, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI